Department of Immunology and Inflammation, Imperial College London, London, UK.
J Infect Dis. 2023 Aug 4;228(Suppl 1):S1-S3. doi: 10.1093/infdis/jiad106.
The COVID-19 pandemic represented 1 of the more significant and unique public health challenges facing the global community, particularly afflicting those with compromised immune systems. These immunocompromised individuals were readily recognized as a group at high risk of infection by SARS-CoV-2 and the associated severe outcomes of COVID-19. Although preventive strategies such as vaccination are important, initial clinical vaccine trials did not enroll immunocompromised individuals; in-depth evaluations of the safety, immunogenicity, and real-world outcomes associated with these vaccines were conducted in this population thereafter. As immunogenicity data of COVID-19 vaccination among this disparate group of individuals emerged, vaccination strategies were adapted to address outstanding challenges and further protect the entirety of this population. This 8-part journal supplement characterizes in-depth the mRNA-based COVID-19 vaccination strategies across the spectrum of immunocompromised individuals, focusing on the ongoing approaches to challenges facing this group as the pandemic continues to evolve.
新型冠状病毒肺炎（COVID-19）大流行是全球面临的更重大和独特的公共卫生挑战之一，尤其影响免疫系统受损者。这些免疫功能低下者被认为是极易感染严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）并发生 COVID-19 相关严重后果的高危人群。虽然疫苗接种等预防策略很重要，但最初的临床疫苗试验并未纳入免疫功能低下者；此后，对这些疫苗的安全性、免疫原性和真实世界结局进行了深入评估。随着这一异质人群 COVID-19 疫苗接种的免疫原性数据的出现，疫苗接种策略进行了调整，以应对突出的挑战，进一步保护这一人群的整体健康。本 8 部分期刊增刊深入探讨了针对免疫功能低下个体的基于信使 RNA（mRNA）的 COVID-19 疫苗接种策略，重点关注随着大流行的持续演变，该人群面临的挑战的持续应对方法。
